Skip to main content

Genprex, Inc. (GNPX)

NASDAQ: GNPX · IEX Real-Time Price · USD
2.85
0.00 (-0.04%)
After-hours:Sep 17, 2021 5:49 PM EDT
2.85
0.13 (4.78%)
At close: Sep 17, 4:00 PM
Market Cap135.45M
Revenue (ttm)n/a
Net Income (ttm)-18.48M
Shares Out47.37M
EPS (ttm)-0.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume492,549
Open2.69
Previous Close2.72
Day's Range2.64 - 2.85
52-Week Range2.24 - 7.72
Beta-0.96
AnalystsStrong Buy
Price Target6.50 (+128.1%)
Est. Earnings DateNov 11, 2021

About GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in precli...

IndustryBiotechnology
IPO DateMar 29, 2018
CEOJ. Rodney Varner
Employees12
Stock ExchangeNASDAQ
Ticker SymbolGNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for Genprex stock is "Strong Buy" and the 12-month stock price forecast is 6.50.

Price Target
$6.50
(128.07% upside)
Analyst Consensus: Strong Buy

News

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...

2 months ago - Business Wire

Genprex to Participate in Upcoming May Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will participate in conferences throughout May 2021.

4 months ago - Business Wire

Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer

Genprex Inc (NASDAQ:GNPX) said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and rela...

4 months ago - Proactive Investors

Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung ...

Genprex Inc (NASDAQ:GNPX) (FRA:2DE) has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung can...

4 months ago - Proactive Investors

Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming A...

4 months ago - Proactive Investors

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for its combination clinical trial of REQORSA and Tagrisso in NSCLC

4 months ago - Business Wire

Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recogn...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex will receive the License of the Year award from University of Pittsburgh on April 22 for advances made on gene therapy program in diabetes.

4 months ago - Business Wire

Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research m...

Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemothe...

5 months ago - Proactive Investors

Wall Street starts in the red

10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX)  presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...

Other symbols:ALTKTRA
5 months ago - Proactive Investors

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer ...

AUSTIN, Texas--(BUSINESS WIRE)--Genprex collaborators report new, positive preclinical data for its lead drug candidate, REQORSA, at the 2021 AACR Annual Meeting.

5 months ago - Business Wire

Genprex targets non-small cell lung cancer and diabetes via gene therapy

Focused on developing life-changing therapies for patients with cancer and diabetes  Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with the ...

5 months ago - Proactive Investors

Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

AUSTIN, Texas--(BUSINESS WIRE)--Genprex' EVP and Chief Operating Officer will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

5 months ago - Business Wire

Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting

Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in two ...

5 months ago - Proactive Investors

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two P...

AUSTIN, Texas--(BUSINESS WIRE)--Preclinical Data for Genprex' TUSC2 Immunogene Therapy Will Be Featured in Two Presentations at the 2021 AACR Annual Meeting

5 months ago - Business Wire

Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's President and CEO will present at the Virtual Oncology Investor Conference on March 29

5 months ago - Business Wire

Genprex to Participate in Upcoming March Investor Conferences

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at upcoming investor conferences in March 2021.

6 months ago - Business Wire

Genprex announces $25 million registered direct offering priced at-the-market

Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stoc...

7 months ago - Proactive Investors

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

7 months ago - Business Wire

Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs

Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs.  Comprised of preeminent clinical specialists, the ...

7 months ago - Proactive Investors

Genprex Announces Formation of Clinical Advisory Board

AUSTIN, Texas--(BUSINESS WIRE)--Genprex forms a Clinical Advisory Board.

7 months ago - Business Wire

Genprex Recognizes World Cancer Day

AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.

7 months ago - Business Wire

Genprex Issues Shareholder Letter and Provides Corporate Update

AUSTIN, Texas--(BUSINESS WIRE)--Genprex issues January 2021 shareholder letter.

7 months ago - Business Wire

Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on February 4 at the Virtual Investor Conference.

7 months ago - Business Wire

The 17 Stocks That Outperformed Tesla In 2020

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued...

7 months ago - Seeking Alpha

Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo

AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.

7 months ago - Business Wire